相关实验视频

Updated: Jul 15, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

针对FLT3治疗疾病:FLT3抑制剂

Qing-Yun Rong¹, Yu Lu¹, Wen Zhang¹

¹College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, PR China.

Drug discovery today

|April 27, 2025

概括

类似FMS的铁激酶3 (FLT3) 抑制剂治疗急性髓性白血病 (AML),但耐药性是一个问题. 本综述涵盖FLT3抑制剂研究,耐药性机制和克服它们的策略.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

类似FMS的氨酸激酶3 (FLT3) 是一种受体氨酸激酶,对造血干细胞和祖细胞发育至关重要.
FLT3突变是血液恶性瘤的常见驱动因素,特别是急性髓性白血病 (AML).
已批准的FLT3抑制剂已在AML治疗中表现出有效性,但由于获得的耐药性而面临重大挑战.

研究的目的:

审查AML治疗中FLT3抑制剂的当前情况.
阐明FLT3抑制剂耐药性的基础机制.
提出克服抗药性和改善AML治疗结果的策略.

主要方法:

关于FLT3抑制剂在AML中的临床前和临床研究的综合文献综述.
对FLT3突变和抵抗机制的已公布数据的分析.
综合当前的研究成果和治疗方法.

主要成果:

几种FLT3抑制剂已被批准用于AML,针对特定突变.
抵抗的机制包括FLT3中的二次突变,绕道信号通路的激活和克隆异质性.
新兴的策略包括组合疗法,下一代抑制剂和向耐药性途径.

结论:

FLT3 抑制剂代表了AML治疗的重大进展.
了解和克服耐药性对于持久的临床反应至关重要.
未来的研究应该专注于开发新的治疗策略,以对抗AML中的FLT3抑制剂耐药性.

关键词:

在AML,AML就是AML.这是一种FLT3抑制剂.吉尔特里尼尼比 (Gilteritinib) 是一种天然的药物.

更多相关视频

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...